Sector News

Shire buys Meritage Pharma for $70m

February 25, 2015
Life sciences
Shire has bought Meritage Pharma for an upfront fee of $70 million and the promise of additional development and regulatory milestone payments, in a move that will add another experimental rare disease drug to its pipeline.
 
The deal gives Shire global rights to Meritage’s lead compound Oral Budesonide Suspension (OBS), which is ready for Phase III trials assessing its potential to treat adolescents and adults with eosinophilic esophagitis (EoE), a rare, chronic inflammatory gastrointestinal disease. 
 
“The acquisition of Meritage by Shire, a global biotechnology company with GI and rare disease expertise, may benefit physicians and patients by helping develop OBS to potentially become the first approved treatment in the US indicated for this often disabling disease,” said Meritage’s President and Chief Executive Officer, Elaine Phillips, commenting on the deal.
 
Shire obtained the rights to acquire Meritage in connection with its acquisition of ViroPharma in 2014, and notes that the move further enhances its late-stage pipeline and builds upon its rare disease/GI commercial infrastructure and expertise. 
 
The group is not expecting the deal to change its earnings guidance for 2015.
 
The deal comes hot on the heels of Shire’s purchase of NPS for $5.2 billion in January, an acquisition that will help achieve its target of doubling revenues to $10 billion a year by 2020, and industry observers believe this isn’t the last of its buying spree.
 
By Seline McKee
 
Source: Pharma Times

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.